CDX
DU 145
Tumor indication
Prostate
Tumor subtype
Prostate Prostate Carcinoma (derived from brain)
Description
DU 145 (Prostate Cancer CDX Model)
The DU 145 prostate cancer cell line was derived from a brain metastasis of prostate carcinoma. It is androgen-independent, providing a model for advanced and treatment-resistant disease. DU 145 has been widely applied in prostate cancer drug discovery. Its metastatic origin makes it valuable for translational research in late-stage cancer.
Key Features:
- Derived from prostate carcinoma brain metastasis.
- Androgen-independent prostate cancer model.
- Expresses low levels of PSA.
- Consistent tumor formation in xenografts.
Applications:
DU 145 is applied in studies of castration-resistant prostate cancer biology. It supports evaluation of novel therapeutics beyond androgen receptor targeting. Researchers use it to investigate resistance pathways in advanced disease. Its metastatic origin provides relevance for late-stage prostate cancer research.
Details
- Tumor indication
- Prostate
- Tumor subtype
- Prostate Prostate Carcinoma (derived from brain)
- Organism
- Human
- Mouse sex
- Male
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.